SYnAbs and Univercells announce strategic agreement on biosimilar mAb
71st AACC Annual Scientific Meeting Press ProgramSYnAbs and Univercells, two neighboring companies based in Gosselies, Belgium, today announce strategic deal signature. Under the terms of the agreement, SYnAbs will develop an immuno-assay in order to measure a confidential biosimilar monoclonal antibody developed by Univercells.